Japan Women’s Health Diagnostics Market Report by Type (Diagnostic Devices, Diagnostic Tests), Application (Breast Cancer, Infectious Disease Testing, Osteoporosis Testing, Pregnancy and Fertility Testing, Sexually Transmitted Disease Testing, and Others), End User (Hospital and Diagnostics Centers, Home Care), and Region 2025-2033

Market Overview:

Japan women’s health diagnostics market size reached USD 1.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.3 Billion by 2033, exhibiting a growth rate (CAGR) of 7.5% during 2025-2033. The elevating adoption of miniaturized diagnostic devices and test kits for home use is primarily driving the market growth.

Women's health diagnostics play a crucial role in diagnosing a wide range of biological and psychosocial conditions affecting female patients. These diagnostics aid in the identification and management of issues related to sexuality, vaginal health, pregnancy complications, and serious illnesses such as osteoporosis, menopause, as well as specific cancers like breast and cervical cancer. They utilize advanced laboratory tests, medical equipment, and procedures, which encompass biopsy, ultrasound, chemotherapy, and magnetic resonance imaging (MRI). Many healthcare diagnostic centers now provide an extensive array of laboratory testing solutions to improve the diagnosis and treatment of rare diseases and conditions that predominantly affect women.

Japan Women’s Health Diagnostics Market Trends:

The increasing prevalence of health issues affecting the overall well-being of women is a key driving force in the Japan market. Additionally, the growing awareness of the benefits of early diagnosis and a heightened sense of health consciousness are boosting the demand for point-of-care (POC) women's health diagnostics, which is acting as another significant growth-inducing factor. Furthermore, the rising rates of infertility due to stressful lifestyles and increased alcohol and drug consumption are fueling the need for women's health diagnostics to address pregnancy complications and promote healthier lives. Moreover, as menopause can raise the risk of certain medical conditions such as cardiovascular diseases and urinary incontinence, the significant increase in the female population is contributing to market growth. Apart from this, various research studies have indicated that women are more susceptible to psychiatric disorders like depression and anxiety during hormonal changes. This, coupled with initiatives by health agencies in numerous countries to improve women's mental health, is driving market expansion. As such, numerous prominent companies are working on the creation of state-of-the-art diagnostic and imaging devices that are both minimally invasive and capable of delivering quicker and improved diagnostic outcomes. These factors are projected to fuel the regional market in the coming years.

Japan Women’s Health Diagnostics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on type, application, and end user.

Type Insights:

• Diagnostic Devices
  • Biopsy Device
  • Imaging and Monitoring Devices
  • Accessories and Consumables
• Diagnostic Tests
  • Breast Cancer Testing
  • PAP Smear and HPV Test
  • Pregnancy Testing and Ovulation Testing
  • Others

The report has provided a detailed breakup and analysis of the market based on the type. This includes diagnostic devices (biopsy device, imaging and monitoring devices, and accessories and consumables) and diagnostic tests (breast cancer testing, PAP smear and HPV test, pregnancy testing and ovulation testing, and others).

Application Insights:

• Breast Cancer
• Infectious Disease Testing
• Osteoporosis Testing
• Pregnancy and Fertility Testing
• Sexually Transmitted Disease Testing
• Others

A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes breast cancer, infectious disease testing, osteoporosis testing, pregnancy and fertility testing, sexually transmitted disease testing, and others.

End User Insights:

• Hospital and Diagnostics Centers
• Home Care

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospital and diagnostics centers and home care.

Regional Insights:

• Kanto Region
• Kansai/Kinki Region
• Central/ Chubu Region
• Kyushu-Okinawa Region
• Tohoku Region
• Chugoku Region
• Hokkaido Region
• Shikoku Region

The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Latest News and Developments:

• In April 2025, The Japan Ministry of Health, Labour and Welfare approved Genmab’s Tivdak (tisotumab vedotin) developed for the treatment of advanced or recurrent cervical cancer that has advanced on or after chemotherapy treatment. Tivdak is considered the first antibody-drug conjugate (ADC) permitted for individuals with cervical cancer in Japan.
• In March 2025, ASKA Pharmaceutical Corporation, a division of ASKA Pharmaceutical Holdings Co., Ltd. reported that ASKA has started a Phase I/II clinical in Japan for an innovative medication (drospirenone agent, development code: LPRI-CF113, hereafter "the Drug") within obstetrics and gynaecology in Japan, which is owned by Insud Pharma. On June 24, 2024, ASKA filed a request for approval from regulatory authorities in Japan for manufacturing and marketing it as a contraceptive. On December 25, 2024, ASKA revealed the broadening of its collaboration with Insud Pharma and the finalization of a licensing contract for the Drug.
• In March 2025, Japan introduced WaiSE, a women’s health app based on sex-/gender-specific medicine, developed using 10 years of clinical data. It supports diagnosis by considering women's unique symptoms and social factors, aiming to improve healthcare access and accuracy. Led by Dr. Katai Miyuki, the initiative bridges gender gaps in medical treatment.
• In January 2025, JUNE MEDICAL, a globally recognized provider of innovative medical devices, and Aspen Surgical, a top supplier of surgical instruments, have revealed a strategic partnership to distribute the Galaxy II retractor system throughout the U.S. market. This collaboration will utilize Aspen Surgical’s sales network to enhance access to JUNE MEDICAL’s Galaxy II retractor system, an adaptable surgical instrument that has revolutionized retraction across various specialties, including general surgery, orthopaedics, gynecology, and more.

Japan Women’s Health Diagnostics Market Report Coverage:

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Japan women’s health diagnostics market from 2019-2033.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the Japan women’s health diagnostics market.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Japan women’s health diagnostics industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.